Cannabis Products: FDA Asks Dosing, Research Incentive Questions
The public hearing on cannabis and cannabis-derivative products also included calls for Good Manufacturing Practices to be imposed.
You may also be interested in...
US FDA will have to wrestle with a proliferation of medical products that are coming to market via ‘alternative pathways’ that do not neatly fit under – or sometimes deliberately seek to avoid – the agency’s regulatory authorities, acting commissioner says.
President Trump's budget request would boost compounding and vaccines by $5m, but human drugs program would lose $4.8m in training funds.
Deal with Pfizer makes for Theravance’s third large pharma partnership since 2016. AbbVie off-loads Marinol to India’s Alkem, Bausch licenses candidate for rare form of dry eye disease from Novaliq.